Henrik Lund
Directeur/Membre du Conseil chez Oslo Cancer Cluster NCE
Profil
Henrik Lund is currently the Director at Oslo Cancer Cluster NCE and MedCoast Scandinavia.
Previously, he was the Chief Executive Officer and Head-Investor Relations at NEL ASA in 2012 and the CEO and Investor Relations Officer at Bionor Pharma ASA in 2011.
Postes actifs de Henrik Lund
| Sociétés | Poste | Début |
|---|---|---|
Oslo Cancer Cluster NCE
 Oslo Cancer Cluster NCE Miscellaneous Commercial ServicesCommercial Services Oslo Cancer Cluster NCE is an oncology research firm that specializes in developing cancer diagnostics and medicines. The private company is based in Oslo, Norway. | Directeur/Membre du Conseil | 17/06/2011 |
| MedCoast Scandinavia | Directeur/Membre du Conseil | 17/06/2011 |
Anciens postes connus de Henrik Lund
| Sociétés | Poste | Fin |
|---|---|---|
Bionor Pharma ASA
 Bionor Pharma ASA Pharmaceuticals: OtherHealth Technology Bionor Pharma ASA engages in research and development, patenting, and commercialization of products in the pharmaceuticals and biotech industry. The company focuses on the research and development of peptide-based vaccines against viral diseases, primarily HIV. The company was founded on January 2, 1993 and is headquartered in Oslo, Norway. | President | 15/08/2011 |
| NEL ASA | Président | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NEL ASA | Producer Manufacturing |
| Entreprise privées | 3 |
|---|---|
Oslo Cancer Cluster NCE
Oslo Cancer Cluster NCE Miscellaneous Commercial ServicesCommercial Services Oslo Cancer Cluster NCE is an oncology research firm that specializes in developing cancer diagnostics and medicines. The private company is based in Oslo, Norway. | Commercial Services |
Bionor Pharma ASA
Bionor Pharma ASA Pharmaceuticals: OtherHealth Technology Bionor Pharma ASA engages in research and development, patenting, and commercialization of products in the pharmaceuticals and biotech industry. The company focuses on the research and development of peptide-based vaccines against viral diseases, primarily HIV. The company was founded on January 2, 1993 and is headquartered in Oslo, Norway. | Health Technology |
| MedCoast Scandinavia |
